What is the Prognosis?

Post navigation

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Δ

Leukemia vs. lymphoma: What you need to know
Source: Published on 2025-02-20
FAQs: Proposed federal spending cuts and blood cancer research and care
Source: Published on 2025-02-19
Reverb Therapeutics Raises USD $12 Million Seed Round Financing to Harness Cytokine Signaling With its Amplify•R™ Platform
Source: MMRF Published on 2025-02-19
Updates in Multiple Myeloma from ASH 2024
Source: MMRF Published on 2025-02-12
Opna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma
Source: MMRF Published on 2025-02-12
Bold goal, bold action
Source: Published on 2025-02-03
“Stages” of Leukemia: Understanding Classification and Progression
Source: Published on 2025-01-23
Bringing Together the CAR T-Cell Therapy Community
Source: Published on 2025-01-22
Statement from The Multiple Myeloma Research Foundation (MMRF) on Distinguished Business Leader Richard Parsons
Source: MMRF Published on 2024-12-27
Sarclisa (isatuximab): A New Option for Patients With Newly Diagnosed Myeloma Not Eligible for Transplant
Source: MMRF Published on 2024-12-23